Hoth Therapeutics (HOTH) Competitors $1.21 -0.02 (-1.63%) Closing price 04:00 PM EasternExtended Trading$1.23 +0.02 (+1.24%) As of 05:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock HOTH vs. RPTX, INMB, ARTV, IMMX, QNTM, OSTX, MNOV, GNTA, CUE, and ANLShould you be buying Hoth Therapeutics stock or one of its competitors? The main competitors of Hoth Therapeutics include Repare Therapeutics (RPTX), INmune Bio (INMB), Artiva Biotherapeutics (ARTV), Immix Biopharma (IMMX), Quantum Biopharma (QNTM), OS Therapies (OSTX), MediciNova (MNOV), Genenta Science (GNTA), Cue Biopharma (CUE), and Adlai Nortye (ANL). These companies are all part of the "pharmaceutical products" industry. Hoth Therapeutics vs. Its Competitors Repare Therapeutics INmune Bio Artiva Biotherapeutics Immix Biopharma Quantum Biopharma OS Therapies MediciNova Genenta Science Cue Biopharma Adlai Nortye Hoth Therapeutics (NASDAQ:HOTH) and Repare Therapeutics (NASDAQ:RPTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation, dividends and media sentiment. Does the media prefer HOTH or RPTX? In the previous week, Hoth Therapeutics had 2 more articles in the media than Repare Therapeutics. MarketBeat recorded 3 mentions for Hoth Therapeutics and 1 mentions for Repare Therapeutics. Repare Therapeutics' average media sentiment score of 1.88 beat Hoth Therapeutics' score of 0.31 indicating that Repare Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Hoth Therapeutics Neutral Repare Therapeutics Very Positive Which has better earnings & valuation, HOTH or RPTX? Hoth Therapeutics has higher earnings, but lower revenue than Repare Therapeutics. Hoth Therapeutics is trading at a lower price-to-earnings ratio than Repare Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHoth TherapeuticsN/AN/A-$8.19M-$1.07-1.13Repare Therapeutics$53.48M1.33-$84.69M-$2.58-0.64 Do analysts recommend HOTH or RPTX? Hoth Therapeutics currently has a consensus price target of $4.00, indicating a potential upside of 230.58%. Repare Therapeutics has a consensus price target of $4.50, indicating a potential upside of 172.73%. Given Hoth Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Hoth Therapeutics is more favorable than Repare Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hoth Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Repare Therapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has more volatility & risk, HOTH or RPTX? Hoth Therapeutics has a beta of 0.66, suggesting that its share price is 34% less volatile than the S&P 500. Comparatively, Repare Therapeutics has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500. Do institutionals and insiders hold more shares of HOTH or RPTX? 7.1% of Hoth Therapeutics shares are held by institutional investors. Comparatively, 85.1% of Repare Therapeutics shares are held by institutional investors. 6.9% of Hoth Therapeutics shares are held by insiders. Comparatively, 11.5% of Repare Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is HOTH or RPTX more profitable? Repare Therapeutics' return on equity of -78.25% beat Hoth Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Hoth TherapeuticsN/A -114.32% -105.92% Repare Therapeutics N/A -78.25%-66.85% SummaryRepare Therapeutics beats Hoth Therapeutics on 8 of the 14 factors compared between the two stocks. Get Hoth Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HOTH and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HOTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HOTH vs. The Competition Export to ExcelMetricHoth TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.05M$3.09B$5.74B$9.78BDividend YieldN/A2.26%4.40%4.04%P/E Ratio-1.1321.2230.8326.39Price / SalesN/A206.90382.9086.63Price / CashN/A44.2437.7259.11Price / Book1.668.0710.106.62Net Income-$8.19M-$54.08M$3.26B$265.42M7 Day Performance-3.20%3.94%3.90%3.58%1 Month Performance-5.47%3.02%3.73%0.46%1 Year Performance65.75%6.84%37.68%19.41% Hoth Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HOTHHoth Therapeutics2.788 of 5 stars$1.21-1.6%$4.00+230.6%+60.4%$16.05MN/A-1.134Positive NewsRPTXRepare Therapeutics2.8129 of 5 stars$1.54-1.9%$4.50+192.2%-49.1%$67.45M$53.48M-0.60180INMBINmune Bio1.9917 of 5 stars$2.53flat$18.40+627.3%-69.4%$67.26M$10K-1.0210Positive NewsARTVArtiva Biotherapeutics3.3237 of 5 stars$3.10+12.7%$17.00+448.4%-73.6%$67.17M$250K0.0081Positive NewsGap DownIMMXImmix Biopharma3.5914 of 5 stars$2.30+1.3%$7.00+204.3%-1.9%$65.45MN/A-2.999Positive NewsAnalyst DowngradeQNTMQuantum BiopharmaN/A$20.61-8.2%N/AN/A$65.27MN/A-1.47N/AGap DownOSTXOS Therapies2.3483 of 5 stars$2.18+5.8%$18.00+725.7%-41.9%$65.15MN/A-2.53N/ANews CoverageAnalyst ForecastMNOVMediciNova2.417 of 5 stars$1.31flat$7.00+434.4%+7.1%$64.25M$1M-5.2410News CoveragePositive NewsAnalyst ForecastGap UpGNTAGenenta Science2.7563 of 5 stars$3.57+2.1%$25.00+599.5%-13.7%$64.10MN/A0.007Positive NewsGap UpTrading HaltedCUECue Biopharma2.5821 of 5 stars$0.82-0.9%$4.00+388.5%+14.9%$63.47M$9.29M-1.4660Gap DownANLAdlai Nortye1.6406 of 5 stars$1.77+4.8%$9.00+408.2%-43.0%$62.36M$5M0.00127Gap Up Related Companies and Tools Related Companies Repare Therapeutics Alternatives INmune Bio Alternatives Artiva Biotherapeutics Alternatives Immix Biopharma Alternatives Quantum Biopharma Alternatives OS Therapies Alternatives MediciNova Alternatives Genenta Science Alternatives Cue Biopharma Alternatives Adlai Nortye Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HOTH) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hoth Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hoth Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access